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on data from a tacrolimus variability study. Cost data were taken primarily from the 
British National Formulary and 2012–13 NHS tariff information and the analysis was 
performed over a 5-year time horizon. Results: The mean cost per patient (includ-
ing tacrolimus, concomitant immunosuppressive medications, dialysis after graft 
failure, and treatment for acute rejection) was GBP 26,958 with Advagraf versus GBP 
30,379 for Prograf over a 5-year period. The total cost saving (GBP 3,421) was driven by 
reduced Advagraf pharmacy costs and lower dialysis costs resulting from the lower 
proportion of patients with high variability in tacrolimus trough concentrations in 
the Advagraf arm, leading to lower risk of graft failure. ConClusions: Converting 
renal transplant recipients from Prograf to Advagraf was associated with lower 
pharmacy and dialysis costs, with the reduction in dialysis costs being driven by the 
lower proportion of Advagraf patients with high tacrolimus trough concentration 
variability and the resultant improvement in graft survival.
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objeCtives: To compare the CKD5 budget requirements of utilizing epoetin alfa 
Hexal vs. darbepoetin alfa in the German health care system. Methods: Chronic 
kidney disease (CKD) is a condition that is prevalent worldwide, and the num-
ber of patients affected continues to increase. ESAs and iron are the mainstays 
of treatment for haemodialysis patients. The purpose of this pharmacoeconomic 
analysis was to evaluate the cost-effectiveness of the short-acting biosimilar ESA 
epoetin-alfa Hexal (EA) 6,000-8,000 IU per week (TIW) vs. long-acting erythropoiesis-
stimulating agent (ESA) darbepoetin alfa (DA) 30-40 mcg weekly (QW), for treating 
chronic haemodialysis patients. A budget impact model was constructed employ-
ing a payer perspective, per patient with 5 year time horizon. The treatment period 
considered was based on 52 weeks and was aligned with real world clinical experi-
ence data from germany1. Model inputs included: medical treatment, outcomes, 
and health care service utilization from published clinical studies2and summary 
of product characteristics recommendation. Effectiveness of therapeutic alterna-
tives was determined by comparing haemoglobin maintenance rates. Costs pre-
sented reflect 2013 prices. The analysis was performed from the perspective of the 
German health care system. Results: The average expected pharmaceutical costs 
per patient were € 3791 to € 5002 for DA QW (30-40mcg weekly) versus € 2690 to € 3520 
for EA TIW (6,000-8,000IU weekly). Cost-savings associated with utilizing EA TIW 
was 41-42% for comparable DA doses. Previous German research has demonstrated 
that ESA consumption of patients on chronic haemodialysis based on DDD is similar 
for biosimilar and originator ESAs1. ConClusions: In the treatment of chronic 
haemodialysis patients in Germany, epoetin alfa Hexal is projected to provide sub-
stantial savings for the health care system when compared to darbepoetin alfa. 
German stakeholders could consider the extent that darbepoetin alfa is utilized in 
haemodialysis patients. [1] Horbrand et al. Eur J Clin Pharmacol 10/2012. [2] Horl et 
al. Clin. Nephrology 1/2012.
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objeCtives: AKI is common in the ICU and often necessitates the provision of 
renal replacement therapy (RRT). Two main modalities exist: continuous (CRRT) 
or intermittent (IRRT) therapy. Neither modality has been found superior in terms 
of survival. However, dialysis dependence among survivors remains a significant 
medical and economic issue. A recent meta-analysis showed initial IRRT might be 
associated with higher rates of dialysis dependence than initial CRRT. We performed 
a preliminary cost-utility analysis comparing both modalities based on these recent 
data. Methods: We assumed a pool of patients who would potentially be eligible 
for either modality and modeled LYG, QALYs gains and costs comparing initial CRRT 
vs. initial IRRT, all else being the same. Using the US perspective, we designed a 
1-year Markov model with daily cycle and 2 health states (dialysis independence/
dependence). Survival for both modalities was fitted from published estimates 
(Weibull regression). The proportion of dialysis independent survivors was fitted 
from published estimates for CRRT (Weibull regression). IRRT dialysis independence 
estimates were obtained by applying the meta-analysis risk-ratio to the fitted CRRT 
estimates. Sensitivity analysis was conducted on the daily implementation cost 
difference between CRRT and IRRT (from $250 to $1,000; basecase: $500) and the 
risk-ratio for dialysis dependence for IRRT as compared to CRRT (from 1.20 to 3.00; 
basecase: 1.99). Results: The QALYs gain was slightly better for CRRT as compared 
to IRRT (0.301 vs. 0.292 respectively). Despite higher hospitalization costs for CRRT 
($86,397 vs. $83,309 for IRRT), the one-year cumulative total cost including the cost 
of dialysis dependence was similar between the two modalities ($94,286 for CRRT 
vs. $94,118 for IRRT). In the basecase analysis, the ICER of CRRT vs. IRRT was $17,562/
QALY. ConClusions: Initial CRRT may actually be cost-effective as compared to 
initial IRRT by reducing the rate of dialysis dependence among AKI survivors.
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objeCtives: To understand the trends in rate and cost of hospitalizations due to 
Chronic Kidney Disease (CKD) in the U.S. Methods: We analyzed the last five years 
Urinary/KidnEy disordErs – cost studies
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objeCtives: The increasing prevalence of end-stage kidney disease in the UK 
has resulted in a heavy economic burden. The National Institute of Health and 
Care Excellence reported that patients receiving dialysis at home have better 
health outcomes and lower health care resource use. This study aims to assess 
the financial impact of increasing the use of home-based dialyses vs. UK current 
practice. Methods: A Markov model was constructed to estimate the financial 
impact of different dialysis scenarios from the UK payer perspective. We modelled 
prevalent and incident dialysis patient population over 5 years. The current UK 
dialysis modality distribution of 15% prevalent and 20% incident peritoneal dialysis 
(PD), 82% prevalent and 79% incident in-centre haemodialysis (ICHD), 3% prevalent 
and 1% incident conventional home HD (HHD), and 0% high dose HHD was com-
pared to 3 scenarios: 1) Increase high dose HHD to 10% among prevalent patients; 
2) Increase high dose HHD to 10% and PD to 20% among prevalent patients and 
increase PD to 25% among incident patients; 3) Increase high dose HHD to 10% 
and PD to 25% among prevalent patients and increase PD to 30% among incident 
patients. In each scenario, the proportion of patients on ICHD changes accord-
ingly, while conventional HHD is kept constant. Model inputs were from published 
sources. Results: The base case results show that all 3 scenarios result in lower 
costs versus current UK practice. A prevalent population size of 22,654 patients was 
modelled, accounting for an annual incident population size of 5,393 in England. 
Scenario 1 saves £25 million (£559 per patient). Scenario 2 saves £67 million (£1,526 
per patient). Scenario 3 saves £110 million (£2,493 per patient). Sensitivity analyses 
demonstrate consistent results. ConClusions: Under the current UK national 
tariff, increasing the proportion of patients on home-based dialyses is associated 
with lower total health care costs.
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objeCtives: Advagraf® is a once-daily prolonged-release formulation of tacrolimus 
with proven non-inferiority to Prograf®, a twice-daily immediate-release formula-
tion of tacrolimus, in biopsy-proven acute rejection in renal transplant recipients. 
Advagraf is associated with improved adherence compared with Prograf, which may 
ultimately improve long-term outcomes. The present study assessed the budget 
impact of switching patients from Prograf to Advagraf in the UK. Methods: A 
budget impact model was constructed based on published data on acute rejection, 
graft failure and mortality in the UK setting. Patients were assumed to convert from 
Prograf to Advagraf on a 1:1 mg:mg basis. In a study comparing the adherence rates 
between once-daily versus twice-daily formulations of tacrolimus, the proportion 
of patients taking the prescribed number of daily doses was 88.2% in Advagraf 
patients and 78.8% in Prograf patients. The model applied a relative risk of graft 
failure of 3.47 to non-adherent patients based on data from a 2004 meta-analysis. 
Cost data were taken from the British National Formulary and 2012–13 NHS tariff 
information. The analysis was performed over a 5-year time horizon and future costs 
were not discounted, in line with International Society for Pharmacoeconomic and 
Outcomes Research guidelines. Results: Over a 5-year time horizon, the mean cost 
per patient (including tacrolimus, concomitant immunosuppressive medications, 
dialysis after graft failure, and treatment for acute rejection) was GBP 29,290 for 
Advagraf versus GBP 33,032 for Prograf. The total cost saving of GBP 3,742 was driven 
by reduced Advagraf pharmacy costs and lower dialysis costs arising from the lower 
risk of graft failure in the larger proportion of adherent patients in the Advagraf 
arm. ConClusions: Conversion of renal transplant recipients from Prograf to 
Advagraf was associated with lower pharmacy and dialysis costs, with the reduc-
tion in dialysis costs being driven by improved adherence to Advagraf regimen and 
the consequent improvement in graft survival.
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objeCtives: Randomized controlled trials have shown that Advagraf®, a once-daily 
prolonged-release tacrolimus formulation, is non-inferior to Prograf®, a twice-daily 
immediate-release tacrolimus formulation, in terms of biopsy-proven acute rejec-
tion in renal transplant recipients. However, relative to Prograf, Advagraf exhibits 
reduced variability in tacrolimus trough concentration, which has been associated 
with reduced graft failure. Based on these data, the present study evaluated the 
cost of switching UK renal transplant patients from Prograf to Advagraf. Methods: 
UK-specific data on acute rejection, graft failure and mortality were used to 
construct a budget impact model to assess the costs of switching from Prograf 
to Advagraf on a 1:1 mg:mg basis. The model assumed that 3.1% of patients on 
Advagraf had high tacrolimus trough concentration variability compared with 17.4% 
on Prograf, based on a study comparing Advagraf and Prograf pharmacokinetics. The 
model applied a relative risk of graft failure of 2.38 to high variability patients based 
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objeCtives: The primary aim of the study was to estimate costs of treatment for the 
first year after renal transplantation from the perspective of health insurance organi-
zations in Iran. Methods: An Excel-based and a Monte Carlo model were developed 
to determine the treatment costs of current clinical practice in renal transplantation 
therapy (RTT). Inputs were derived from Ministry of Health and insurance organiza-
tions’ database, hospital and pharmacy records, clinical trials and local and interna-
tional literature. According to the model, there were almost 17,000 patients receiving 
RTT in Iran, out of which about 2,200 patients underwent the operation within the 
study year (2011- 2012; n= 2200). Results: The estimated first year total treatment 
cost after renal transplantation was almost $14,000,000. These costs corresponded to 
annual total cost per patient of almost $6500 for the payers. ConClusions: Renal 
transplantation therapy is almost fully reimbursed by government in Iran. However, 
regarding new expensive medicines, cost of medical expenditure is rapidly growing 
and becoming quite unaffordable for the government; therefore, out-of-pocket (OOP) 
payments are dramatically increasing over time. In order to improve reimbursement 
policy making under pressure of current budget constraints, the present study is 
providing decision makers with practical tools make them possible to easily compare 
budgetary impact of the current therapy strategy with the future financial conse-
quences of purchasing newly proposed medicines. In other words having estimation 
of the current budget spending on RTT would help policy makers in making efficient 
resource allocation and decrease quite high OOP expenditures.
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objeCtives: To evaluate resource utilisation for subjects with overactive 
bladder (OAB) syndrome who are managed with the commonly prescribed oral 
medications: solifenacin succinate, tolterodine tartrate, or trospium chloride from 
the payer perspective. Methods: Data were abstracted from medical records for 
qualified subjects who were ≥ 18 years, with a diagnosis for OAB (at least one of the 
following: urgency, frequency with or without urgency incontinence) on or before 
December 31, 2010. Subjects must have been on one of the study medications for at 
least 3 months and have at least 12 months of medical records available. The study 
was approved by local ethics committees and all data provided was anonymised. 
Medication costs for Germany are reported for 2013 € . Results: A total of 136 of 
229 subjects were included for the German analysis. The remaining subjects were 
from the Czech Republic to be reported elsewhere. Top 3 reasons for exclusion from 
Germany include: primary diagnosis of urinary tract infection, urologic surgery 
within 6 months of the data collection, and diabetic neuropathy. The annual overall 
mean cost for office visits, specialist visits, investigations, other treatments, medica-
tions and incontinence pad use with solifenacin (5,10mg/day) (N= 60), trospium (IR 
and ER maximum dose of 60mg/day) (N= 51), and tolterodine (IR 2, 4mg/day and ER 
4mg/day) (N= 25), were € 1,059.31, € 1,247.76, and € 1,626.01, respectively. Incontinence 
pad use for weekly frequency with solifenacin, trospium, and tolterodine was, 17.34, 
19.51 and 20.35, respectively. Overall satisfaction with medication as perceived by 
the clinician (very satisfied, satisfied, neutral, dissatisfied, very dissatisfied) for very 
satisfied and satisfied was 97%, 86%, 100%, for solifenacin, trospium, tolterodine, 
respectively. ConClusions: Solifenacin had the lowest annual cost-in-use com-
pared to other study drug annual cost. This was corroborated in part by the lowest 
incontinence pad use for solifenacin compared to trospium and tolterodine and 
the high treatment satisfaction.
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objeCtives: Urgency urinary incontinence (UUI) has a substantial impact on 
patients’ QOL and well-being, and may pose a substantial economic burden on 
patients and health insurers. We assessed the cost and cost-effectiveness of four 
conservative treatment modalities for UUI in Israel. Methods: A total of 164 
women were randomly allocated to one of four interventions: drug therapy (DT), 
bladder training (BT), pelvic floor muscle-training (PFMT), and combined pelvic floor 
rehabilitation (CPFR) and were followed over a period of 12-months. Resource utili-
zation including physician encounters, dispensed prescriptions, physical therapist 
treatment and any other medical services was estimated for each study participant. 
We also estimated the women’s self-reported utilizations of pads, laundry and new 
underwear. Total costs were calculated by multiplying the volumes of resource uti-
lization by the corresponding unit-prices. We used the bootstrap method to report 
bias-corrected confidence-intervals of cost estimates. Utility weights were elicited 
using the EQ-5D questionnaire at baseline, 3-months and 12-months of follow-
up. Results: Women in all four treatment groups showed improvements in QOL 
from baseline to 12-months (DT:0.87 - 0.93, BT:0.85 to 0.89, PFMT:0.82 - 0.84, CPFR: 
0.82 to 0.86). Changes in QOL summary scores from study enrollment and end of 
follow-up were estimated after correction for potential baseline differences, and 
were not statistically different among study groups. The mean total cost was some-
what lower for the DT group participants ($1,460), as compared with the three other 
interventions (range: $1,760-$1,990). These differences, however, were not statisti-
cally significant. The mean monthly personal costs were significantly reduced from 
baseline to 12-months of follow-up in all treatment groups. ConClusions: The 
four treatment modalities for treating UUI were equally effective and associated 
of hospitalizations with ICD-9 diagnosis codes of CKD and End Stage Renal Disease 
(ESRD). The annual number of hospitalizations for specific diagnosis was obtained 
from AHRQ’s National In-patient Sample (NIS) databases of 2005-2009. Data was 
also analyzed for length of stay (LOS), charges and cost of hospitalization. Results: 
During the last five years the number of hospitalizations with diagnosis of CKD and 
ESRD has increased 4.1 and 4.6 fold, respectively. In 2009, an estimated 1,634,422 
and 931,641 hospitalizations were with diagnosis of CKD and ESRD respectively. The 
mean LOS for patients with CKD increased from 4.9 to 5.5 days between2005-2009. 
The mean LOS for patients with ESRD has remained steady at ~6 days between 2005-
2009. The cost of hospitalization with diagnosis of CKD has increased 31% between 
2005-2009. The cost of hospitalization with diagnosis of ESRD has increased 21% 
between 2005-2009. In 2009, the mean cost of hospitalization for patients with CKD 
and ESRD was $11,209 and $21,358, respectively. ConClusions: Hospitalizations 
due to CKD and ESRD have significantly increased during the last five years. There 
is a need for prevention, treatment, and disease management programs to lower 
the medical and socioeconomic burden of this disease.
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objeCtives: To examine the economic burden and health care utilizations of 
patients diagnosed with chronic kidney disease (CKD) in the U.S. veteran popula-
tion. Methods: A retrospective database analysis was performed using the Veterans 
Health Administration (VHA) Medical SAS datasets (01OCT2008-30SEP2012). Patients 
diagnosed with CKD were identified using International Classification of Disease 9th 
Revision Clinical Modification (ICD-9-CM) diagnosis codes 585.xx, 250.4xx, 791.0x, 583.
xx, and 403.xx. The first diagnosis date was designated as the index date. A group of 
non-CKD patients of the same age, region, gender and index year were identified and 
matched on baseline Charlson Comorbidity Index (CCI) as the comparison group with 
a randomly chosen index date to minimize selection bias. Patients in both groups 
were required to be at least 18 years old, and have continuous health plan benefits 
1 year before and 1 year after the index date. One-to-one propensity score match-
ing was used to compare the health care costs and utilizations during the follow-up 
period between the CKD and comparison groups, adjusted for baseline demographic 
and clinical characteristics. Results: A total of 477,078 patients were identified for 
the CKD cohort and the comparison cohort. After 1:1 matching, 155,324 of patients 
were matched from each group, and the baseline characteristics were well-balanced. 
CKD Patients incurred higher health care utilizations in inpatient (17.00% vs. 2.84%, 
p< 0.01), emergency room (17.81% vs. 6.64%, p< 0.01), physician office (99.28% vs. 67.92%, 
p< 0.01), outpatient (99.36% vs. 68.69%, p< 0.01), and pharmacy visits (91.16% vs. 72.61%, 
p< 0.01). The CKD group also had higher patient expenditures in inpatient ($6,228 vs. 
$802, p< 0.01), emergency room ($194 vs. $62, p< 0.01), physician office ($3,287 vs. $1,516, 
p< 0.01), outpatient ($3,788 vs. $1,715) and pharmacy ($848 vs. $490, p< 0.01) than 
patients in the comparison group. ConClusions: CKD patients had a significantly 
higher burden of illness compared to a similar comparison group of non-CKD patients.
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objeCtives: Itchy and dry skin, symptoms of pruritus, are commonly reported by 
patients with end-stage renal disease (ESRD). Previous analyses of a large dialysis 
organization (LDO) suggested that these symptoms are associated with decreased 
quality of life and poorer health outcomes. As a result, these patients may represent 
a higher economic burden to payers. This retrospective cohort study compared direct 
health care resource utilization (HRU) and costs associated with varying degrees of 
self-reported itchiness/dryness skin severity. Methods: Adult patient data (≥ 18 
years old) from the 2009 United States Renal Disease System (USRDS) dataset were 
combined with corresponding Kidney Disease Quality of Life (KDQOL) survey data 
obtained between January to September 2009, at an LDO. Patients were included if 
they had answered KDQOL itchiness/dryness questions, had KDQOL assessments ≥ 
3 months after starting dialysis, and had Medicare as their primary payer. Patients 
were grouped by their itchiness/dryness severity. All HRU and cost outcomes were 
described over a 3-6 month follow-up period post-KDQOL survey. Patients were 
censored for death, transplant, change in treatment modality, discontinued treat-
ment, or loss of observation during the follow-up period. Results: Study popula-
tion included 1,387 patients. HRU analyses of itchiness showed increased rate of 
hospitalizations (42.5% vs. 28.4%) for patients who were extremely bothered versus 
not bothered by itch. Similar results were observed for dryness (34.3% vs. 27.5%) 
and combined itchiness and dryness (34.2% vs. 28.0%). Extremely bothered patients 
had higher overall health care costs: $33,755 vs. $26,933 for itchiness; $29,801 versus 
$26,321 for dryness; and $29,249 vs. $26,736 for combined itchiness and dryness. 
Dialysis and hospitalization costs contributed the most toward overall health care 
costs. ConClusions: These results suggest an association between increased skin 
itchiness/dryness and increased hospitalizations and health care costs. Additional 
research, adjusting for patient characteristics, is needed to provide more evidence 
for the burden of skin itchiness/dryness in ESRD patients.
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drUGs?
Foroutan N.1, Salamzadeh J.1, Foroutan A.2, Jamshidi H.R.1, Rasekh H.1
